Ocular Toxoplasmosis Treatment Guidelines

Introduction to Treatment Regimens

The American Academy of Pediatrics recommends the gold standard treatment for ocular toxoplasmosis is pyrimethamine plus sulfadiazine plus leucovorin (folinic acid), with corticosteroids added after 72 hours of antimicrobial therapy for vision-threatening lesions near the macula or optic disk 1, 2

Pyrimethamine dosing for ocular toxoplasmosis treatment is a loading dose of 2 mg/kg/day orally divided twice daily for the first 2 days (maximum 50 mg/day), followed by a maintenance dose of 1 mg/kg/day orally once daily (maximum 25 mg/day) 1, 2, 3
Sulfadiazine dosing for ocular toxoplasmosis treatment is a loading dose of 75 mg/kg orally × 1 dose, followed by a maintenance dose of 100 mg/kg/day orally divided twice daily 1, 2, 3
Leucovorin (folinic acid) should be administered at 10-20 mg orally three times per week throughout treatment, and it is critical to note that folic acid cannot substitute for folinic acid 1, 2, 4

Prednisone should be added for severe chorioretinitis threatening vision (macular or optic disk involvement) at a dose of 1 mg/kg/day divided twice daily (maximum 40 mg/day), starting after 72 hours of antimicrobial therapy, and continuing until resolution of severe inflammation, then rapid taper 1, 2, 4

Treatment for ocular toxoplasmosis should be continued for at least 1-2 weeks after complete resolution of all clinical signs and symptoms, with a total duration of 4-6 weeks 1, 4, 5

For sulfa-allergic patients, pyrimethamine plus clindamycin is the preferred alternative, although some experts have used pyrimethamine plus azithromycin, with a randomized trial demonstrating similar efficacy to pyrimethamine plus sulfadiazine but with significantly fewer adverse effects 2, 4, 5
Trimethoprim-sulfamethoxazole (TMP-SMX) can be administered for 6 weeks in acquired ocular toxoplasmosis, with longer courses required for extensive disease or poor response 2, 5

Complete blood count must be performed at least weekly while on daily pyrimethamine and at least monthly while on less than daily dosing to monitor for bone marrow suppression, as pyrimethamine-sulfadiazine therapy carries significant risk of bone marrow suppression, particularly neutropenia, especially when leucovorin is not administered 2, 3, 4

There are no comparative pediatric trials on the relative efficacy of different treatment regimens for acute toxoplasmic chorioretinitis, and in the adult literature, only a few comparative trials exist, with a lack of high-quality evidence to determine the best treatment option 4

Inadequate duration of therapy may lead to relapse, particularly in immunocompromised patients, with a mean recurrence rate after 3 years of approximately 49%, and starting corticosteroids before antimicrobial therapy can worsen infection—always wait 72 hours after initiating antimicrobials 1, 2, 5
Using folic acid instead of folinic acid (leucovorin) will not prevent bone marrow suppression and is a critical error 4

The Centers for Disease Control and Prevention recommends pirimetamin + klindamisin as an alternative therapy for patients with sulfa allergy 6
Dapson + pirimetamin + leukovorin can be considered for Toxoplasma seropositive patients who cannot tolerate TMP-SMZ, with a strength of evidence based on recommendations from the Centers for Disease Control and Prevention and the Annals of Internal Medicine 7, 8
Atovaquone with or without pirimetamin is another option, although it is substantially more expensive, according to the Centers for Disease Control and Prevention and the Annals of Internal Medicine 7, 8

The Centers for Disease Control and Prevention recommends lifelong maintenance therapy for immunocompromised patients with CD4+ <100 cells/µL after acute therapy to prevent relapse 6, 7, 8

The American Academy of Pediatrics recommends close ophthalmologic follow-up every 2-3 weeks for all cases of active Toxoplasma chororetinitis to determine the optimal duration of therapy 9